GH Research PLC (GHRS)
$18.85-5.84%Close
SELLCRISIS · day 14
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $1.3B
- Beta
- 1.32
- P/E (TTM)
- -18.85
- Short % float
- 3.47%
- Days to cover
- 5.0
- SI change
- -34.8%
- 1W
- -12.41%
- 1M
- -32.41%
- vs SPY 1W
- -12.27%
- vs SPY 1M
- -34.92%
Industry peers
FMP comparable companies · ranked by market cap
- DFTXSELLDefinium Therapeutics, Inc.$4.7BBEARQ 26$35.20-2.33%
- BHVNSELLBiohaven Ltd.$1.8BCRISISQ 16$11.81-3.30%
- RAPPSELLRapport Therapeutics, Inc. Common Stock$1.4BCRISISQ 24$30.15-3.85%
- LBRXSELLLB Pharmaceuticals Inc Common Stock$1.0BCRISISQ 75$35.93-3.17%
- SPTXSELLSeaport Therapeutics, Inc. Common Stock$918MQ -13$17.15-6.24%
- ANROSELLAlto Neuroscience, Inc.$848MCRISISQ 15$24.15-8.53%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on GHRS?
- LOPJLB’s latest quantitative signal on GH Research PLC (GHRS) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is GHRS in?
- GH Research PLC (GHRS) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does GH Research PLC (GHRS) do?
- GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, specifically targeting patients with treatment-resistant depression (TRD). Its most advanced program is GH001, an inhalable 5-MeO-DMT product candida…